体重对脓毒性休克患者固定剂量血管加压素反应的影响
该单中心回顾性队列纳入938例在医疗、外科或神经科学ICU接受固定剂量血管加压素至少6小时并联用儿茶酚胺的脓毒性休克患者。采用Spearman相关分析体重和BMI调整的血管加压素剂量与儿茶酚胺剂量变化及MAP变化的关系。结果显示,体重调整剂量与2小时儿茶酚胺剂量变化(r=-0.05,P=0.13)和MAP变化(r=0.04,P=0.31)均无相关性,6、12小时及BMI调整分析亦均P>0.05。按WHO BMI分组后,机械通气时间、无ICU天数及院内死亡率(64.8%)均无差异。
要点
- 938例脓毒性休克患者中,体重调整血管加压素剂量与2小时儿茶酚胺剂量变化无相关性(r=-0.05,P=0.13)。
- 体重调整血管加压素剂量与2小时MAP变化无相关性(r=0.04,P=0.31),6、12小时及BMI调整分析均P>0.05。
- 按WHO BMI分组(<25、25-30、30-35、>35)后,机械通气时间(P=0.59)、无ICU天数(P=0.83)和院内死亡率(P=0.35)均无差异。
- 院内死亡率为64.8%,各BMI组间无差异。
适用人群与场景
- 在医疗、外科或神经科学ICU接受固定剂量血管加压素至少6小时并联用儿茶酚胺的脓毒性休克患者。
研究设计与关键结果
- 单中心回顾性队列,纳入938例脓毒性休克患者,中位体重86.3(70.6-106.6)kg,中位BMI 29.5(24.9-36.2)kg/m²。
- 体重调整血管加压素剂量与2小时儿茶酚胺剂量变化无相关性(r=-0.05,P=0.13),与2小时MAP变化无相关性(r=0.04,P=0.31)。
- 6小时和12小时儿茶酚胺剂量变化及MAP变化与体重调整剂量亦无相关性(所有P值>0.05)。
- BMI调整血管加压素剂量与各时间点MAP变化及儿茶酚胺剂量变化均无相关性(所有P值>0.05)。
- BMI分组:<25为238例(25.4%),25-30为254例(27.1%),30-35为182例(19.4%),>35为264例(28.1%)。
- 中位机械通气时间3.99(1.50-5.07)天,中位无ICU天数0(0-1.6)天,按BMI分层无差异(P=0.59和P=0.83)。
- 院内死亡率为64.8%,各BMI组间无差异(P=0.35)。
证据类型、等级与局限
- 证据类型:单中心回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在该大型脓毒性休克队列中,按体重和BMI调整血管加压素剂量未影响儿茶酚胺剂量或MAP的变化,机械通气时间、无ICU天数及死亡率亦不受BMI影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: The effect of patient weight and body mass index (BMI) on hemodynamic response to vasoactive medications is not fully understood. In titratable vasopressors, this effect is less likely a concern due to the ability to titrate dose to response; however, with the use of fixed-dose vasopressin, patient weight and BMI may impact response.
METHODS: This was a single-center, retrospective cohort of patients who received fixed-dose vasopressin for septic shock for at least 6 h with concomitant catecholamines in the medical, surgical, or neurosciences intensive care unit (ICU) at a tertiary care center. The association of weight- and BMI-adjusted vasopressin dose with change in catecholamine dose and change in mean arterial pressure (MAP) were evaluated using Spearman's correlation. Patients were further stratified by World Health Organization BMI categories to evaluate secondary outcomes.
RESULTS: There were 938 patients included with a median weight of 86.3 (70.6-106.6) kg and BMI of 29.5 (24.9-36.2) kg/m. There was no correlation between weight-adjusted vasopressin dose and change in catecholamine dose (r = -0.05, P = 0.13) or change in MAP (r = 0.04, P = 0.31) 2 h after initiation of vasopressin. Similarly, no correlation was found when evaluating change in catecholamine dose or MAP at 6 and 12 h after vasopressin initiation (all P values >0.05). Comparable findings were observed when evaluating correlations between BMI-adjusted vasopressin dose with change in MAP and catecholamine dose at all time points (all P values >0.05). BMI groupings were balanced with 238 patients (25.4%) having a BMI less than 25, 254 patients (27.1%) having BMI 25 to 30, 182 patients (19.4%) having BMI 30 to 35, and 264 patients (28.1%) having BMI more than 35. The median duration of mechanical ventilation and ICU free days were 3.99 (1.50-5.07) and 0 (0-1.6) days, respectively, with no differences observed when stratified by BMI (P = 0.59 and P = 0.83, respectively). In-hospital mortality was 64.8% and there was no difference among BMI groups (P = 0.35).
CONCLUSIONS: In this large cohort of septic shock patients, adjusting vasopressin dose for weight and BMI did not impact changes in catecholamine doses or MAP. Duration of mechanical ventilation, ICU free days, and mortality after vasopressin initiation were not affected by BMI.
参考来源
- Torbic H, Sacha GL, Bauer SR, et al. Body Mass's Impact on Response to Fixed-Dose Vasopressin in Patients With Septic Shock. Shock. 2018. PMID: 29240642. doi:10.1097/SHK.0000000000001086
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。